{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Combination Treatment for Endometrial Cancer Significantly Improves PFS

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify a prognostic indicator for women with endometrial cancer.
  2. Explain results from the phase III NRG GY018 study that combined immunotherapy with chemotherapy to treat women with advanced-stage or recurrent endometrial cancer.

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of the role of pembrolizumab combined with carboplatin and paclitaxel for the treatment of women with advanced or recurrent/advanced endometrial cancer by achieving a minimum score of 70% on the outcomes-based posttest.

Disclosures

All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $12.95

Credits:

Planner
Test Code: OT0523
Published: May 2023
Expires: 3/6/2026
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Advanced Practice Nursing , Cancer , Gynecological , Women's Health
Specialties: Advanced Practice Nursing, Gynecology, OB/GYN, Oncology, Women's Health
Topics: Cancer , Chemotherapy